Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
This is a comment on Pharmaceuticals 2010, 3(6), 1909-1935 .

Pharmaceuticals 2010, 3(12), 3629-3632; doi:10.3390/ph3123629
Commentary

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’

*  and
Received: 9 November 2010; Accepted: 16 December 2010 / Published: 17 December 2010
(This article belongs to the Special Issue Antiepileptic Drugs)
View Full-Text   |   Download PDF [49 KB, updated 20 December 2010; original version uploaded 17 December 2010]
Abstract: The recent review of Matthew D. Krasowski on ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’ is a useful foundation of comparative interpretations on our current knowledge about therapeutic drug monitoring. Within the review, the statement that therapeutic drug monitoring has a minimal role in the therapeutic use of eslicarbazepine acetate due to its relatively predictable pharmacokinetics reflects the existing body of evidence although some information such as eslicarbazepine acetate’s chemical structure, proportions of its metabolites, their pharmacokinetics and chiral method of plasma level measurement need to be revised. These critical characteristics differentiate the novel compound from former dibenzazepines such as carbamazepine and oxcarbazepine in its clinical effects and needs for therapeutic drug monitoring.
Keywords: anticonvulsants; anti-epileptic drugs; drug monitoring; drug toxicity; epilepsy; seizures; carbamazepine; oxcarbazepine; eslicarbazepine acetate anticonvulsants; anti-epileptic drugs; drug monitoring; drug toxicity; epilepsy; seizures; carbamazepine; oxcarbazepine; eslicarbazepine acetate
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Öztiryaki, A.H.; Soares-da-Silva, P. Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’. Pharmaceuticals 2010, 3, 3629-3632.

AMA Style

Öztiryaki AH, Soares-da-Silva P. Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’. Pharmaceuticals. 2010; 3(12):3629-3632.

Chicago/Turabian Style

Öztiryaki, Ahmet H.; Soares-da-Silva, Patricio. 2010. "Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’." Pharmaceuticals 3, no. 12: 3629-3632.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert